Etanercept biosimilar (Coherus Biosciences)

依那西普生物类似药 (Coherus Biosciences)

Report date: 2022/07/04 19:38:02

Base Information

Drug NameEtanercept biosimilar (Coherus Biosciences)

Drug Alias Name依那西普生物仿制药 (Coherus Biosciences)CHS-0214BAX-2200

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion proteinBiologics > Biosimilar

Mechanisms of ActionTumor necrosis factor β inhibitorsTumor necrosis factor α inhibitors

TargetsTumor necrosis factor βTumor necrosis factor α

Therapy Area/IndicationsPlaque psoriasisArthritis, Rheumatoid

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanadaUnited StatesPoland +[14]

CombinationsNo

Global Highest StatusPending (Phase 3 Clinical)

Highest Status in ChinaN/A

China Registration ClassN/A

Active CompaniesN/A

Active IndicationsN/A

Inactive IndicationsPlaque psoriasisArthritis, Rheumatoid

ATC CodeL04AB01